ClinicalTrials.gg
CompletedNCT07110441Updated Jan 16, 2026

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

A Phase 1 interventional study of Single Dose G1090N and Multiple dosing of G1090N in Acute-on-Chronic Liver Failure, sponsored by Genfit. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Genfit · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects

02

Conditions studied

  • Acute-on-Chronic Liver Failure

Keywords

  • Acute-on-Chronic Liver Failure; ACLF; G1090N, Tizoxanide, Nitazoxanide, Pharmacokinetics, Healthy volunteer
03

In context

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

This study's enrollment of 52 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.

Browse Acute-On-Chronic Liver Failure studies →

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Healthy subjects with absence of abnormalities as determined by the Investigator or medically qualified designee based on a detailed medical history and complete physical examination;
  • 2. Clinical laboratory test results for liver and renal function within the normal reference range. For all other clinical laboratory parameters, results outside the normal reference range to be confirmed by the Investigator and the Sponsor as not clinically significant;
  • 3. Male or female subjects ≥18 and ≤55 years of age with a minimum body weight of 50 kg and a of ≥18.0 to ≤30.0 kg/m2 at the time of signing the form (ICF);
  • 4. Subjects willing and able to comprehend and sign informed consent and to comply with the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  • 1. Significant history or clinical manifestation of any metabolic (including thyroid), allergic, dermatological, hepatic (including Gilbert's syndrome), renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal, neurological, or psychiatric disorder;
  • 2. Experienced an acute illness within 14 days of SCR;
  • 3. Positive serologic test for surface antigen, or for virus antibody, or I and II at SCR; positive coronavirus disease 2019 test at Day -1 of Part 1 or Part 2;
  • 4. Frequent headaches (more than twice a month) and/or migraines, recurrent nausea and/or vomiting, or diarrhea;
  • 5. Smokers, defined as having used tobacco- or nicotine-containing products within 6 months prior to SCR;
  • 6. Out-of-range vital signs at rest (ie, supine for at least 5 minutes) at SCR and Day -1 of Part 1 and Part 2, defined as:

    1. Systolic blood pressure (SBP) \<90 mm Hg or >140 mm Hg;
    2. Diastolic blood pressure (DBP) \<50 mm Hg or >90 mm Hg;
    3. Pulse rate \<50 bpm or >90 bpm; For these parameters, out-of-range values that are not (as determined by the Investigator) may be repeated twice during SCR and the subject may be enrolled if at least one repeated value is within the range noted above;
  • 7. Symptomatic hypotension at SCR, regardless of the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP ≥20 mm Hg or DBP ≥10 mm Hg within 3 minutes when changing from the supine to the standing position;
  • 8. Out-of-range 12-lead (ECG) recordings at SCR defined as:

    1. PR ≤120 ms or ≥220 ms;
    2. QRS >120 ms;
    3. corrected for heart rate using Fridericia's method ≥450 ms; For these parameters, out-of-range values that are not clinically significant (as determined by the Investigator) may be repeated twice during SCR and Day -1 and the subject may be enrolled if at least 1 repeated value is within the normal ranges noted above; Subjects must also have no sign of any clinically significant irregularity in heart rhythm.
  • 9. Use of any prescription or nonprescription drugs or substances (including vitamins and dietary or herbal supplements) within 30 days or 5 half-lives, if known, of the respective drug or substance, whichever is longer, prior to medicinal product (IMP) administration, unless deemed acceptable by the Investigator and Sponsor;
  • 10. Vaccination with a within 6 months prior to first dosing or vaccination with an inactivated vaccine (eg, inactivated influenza vaccines or severe acute respiratory syndrome coronavirus 2 vaccines) within 30 days prior to first dosing;
  • 11. Receipt of NTZ, or any investigational product within 30 days, or 5 half-lives, if known, of the respective investigational product, whichever is longer, prior to SCR;
  • 12. History of alcohol consumption defined as >30 g pure alcohol/day for men, and >20 g pure alcohol/day for women within the last year, or any alcohol consumption within 48 hours prior to SCR or Day -1 for Part 1 and Part 2;
  • 13. Consumption of caffeine- or xanthine-containing products (>4 cups or glasses per day of eg, coffee, tea, cola drinks, and chocolate) within 48 hours prior to SCR or Day -1 for Part 1 and Part 2;
  • 14. Subjects following a vegan or vegetarian diet or any other dietary restrictions;
  • 15. Strenuous exercise within 24 hours prior to SCR or Day -1 for Part 1 and Part 2;
  • 16. Blood donation or blood loss (excluding volume drawn at SCR) of 50 to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to IMP administration;
  • 17. Receipt of blood products within 2 months prior to SCR;
  • 18. History of a major surgical procedure within 6 months prior to SCR. (NOTE: subjects may have had a cholecystectomy, provided not within 3 months of SCR and no complications with cholecystectomy);
  • 19. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (eg, bariatric-metabolic surgery, etc.);
  • 20. Poor peripheral venous access;
  • 21. Known to the IMP or any of its formulation ;
  • 22. History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results, or put the subject at undue risk;
  • 23. Pregnancy or lactation;
  • 24. Women of and non-sterile men who are not willing to use adequate for the full duration of the study and for 90 days after the last dose of IMP.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    G1090N 300 mg

    Subjects will recieve a single dose of G1090N

    Drug: Single Dose G1090N

  • Experimental
    G1090N 600 mg

    Subjects will recieve single and multiple doses of G1090N

    Drug: Single Dose G1090N · Drug: Multiple dosing of G1090N

  • Experimental
    G1090N 900 mg

    Subjects will recieve single and multiple doses of G1090N

    Drug: Single Dose G1090N · Drug: Multiple dosing of G1090N

  • Experimental
    G1090N 1200 mg

    Subjects will recieve single and multiple doses of G1090N

    Drug: Single Dose G1090N · Drug: Multiple dosing of G1090N

Interventions

  • DrugSingle Dose G1090N

    Subjects will receive single ascending doses of G1090N up to 1200mg.

  • DrugMultiple dosing of G1090N

    Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax)

    To evaluate pharmacokinetics (PK) following single and multiple ascending dose administration of G1090N in healthy subjects. Plasma PK parameters will be determined for tizoxanide (TZ) and tizoxanide glucuronide (TZG) concentrations including but not limited to Cmax.

    Time frame: Up to Day 9

  2. Time to Cmax (tmax)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Plasma PK parameters will be determined for TZ and TZG concentrations including but not limited to tmax.

    Time frame: Up to Day 9

  3. Area under the plasma concentration-time curve (AUC)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Plasma PK parameters will be determined for TZ and TZG concentrations including but not limited to AUC.

    Time frame: Up to Day 9

  4. Terminal half-life (t1/2)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Plasma PK parameters will be determined for TZ and TZG concentrations including but not limited to t1/2.

    Time frame: Up to Day 9

  5. Amount excreted (Ae)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Urine PK parameters will be determined for TZ and TZG concentrations including but not limited to Ae.

    Time frame: Up to Day 8

  6. Renal clearance (CLr)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Urine PK parameters will be determined for TZ and TZG concentrations including but not limited to CLr.

    Time frame: Up to Day 8

  7. Fraction of dose excreted (fe)

    To evaluate PK following single and multiple ascending dose administration of G1090N in healthy subjects. Urine PK parameters will be determined for TZ and TZG concentrations including but not limited to fe.

    Time frame: Up to Day 8

Secondary outcomes

  1. To evaluate safety and tolerability following single and multiple ascending dose administration of G1090N in healthy subjects

    Observed values and change from baseline, when relevant, for clinical laboratory safety parameters, vital signs measurements, 12-lead ECG parameters, and physical examinations. Safety and tolerability defined as the incidence and severity (NCI CTCAE v5.0 grade) of TEAEs including SAEs (comprising clinically significant findings on vital signs, physical examination, ECG, and laboratory parameters including change from baseline).

    Time frame: from baseline up to Day 14

07

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Dec 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 7, 2025
StartActual
Aug 26, 2025
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 3, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07110441
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Aug 26, 2025
Primary completion
Dec 1, 2025
Completion
Dec 3, 2025
Last update
Jan 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion